相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。The novel EZH2 inhibitor, GSK126, suppresses cell migration and angiogenesis via down-regulating VEGF-A
Ya-Tian Chen et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2016)
STRAP mediates the sternness of human colorectal cancer cells by epigenetic regulation of Notch pathway
Lin Jin et al.
CANCER RESEARCH (2016)
Combined Inhibition of DNMT and HDAC Blocks the Tumorigenicity of Cancer Stem-like Cells and Attenuates Mammary Tumor Growth
Rajneesh Pathania et al.
CANCER RESEARCH (2016)
The epigenetics of tumour initiation: cancer stem cells and their chromatin
Alexandra Avgustinova et al.
CURRENT OPINION IN GENETICS & DEVELOPMENT (2016)
ENGAGE-501: phase II study of entinostat (SNDX-275) in relapsed and refractory Hodgkin lymphoma
Connie Lee Batlevi et al.
HAEMATOLOGICA (2016)
Targeting histone methylation for cancer therapy: enzymes, inhibitors, biological activity and perspectives
Yongcheng Song et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2016)
Identification of a Benzoisoxazoloazepine Inhibitor (CPI-0610) of the Bromodomain and Extra-Terminal (BET) Family as a Candidate for Human Clinical Trials
Brian K. Albrecht et al.
JOURNAL OF MEDICINAL CHEMISTRY (2016)
Association of Histone Methyltransferase G9a and Overall Survival After Liver Resection of Patients With Hepatocellular Carcinoma With a Median Observation of 40 Months
Kai Bai et al.
MEDICINE (2016)
Prognostic Significance of EZH2 Expression in Non-Small Cell Lung Cancer: A Meta-analysis
Xinhua Wang et al.
SCIENTIFIC REPORTS (2016)
ENGAGE-501: phase II study of entinostat (SNDX-275) in relapsed and refractory Hodgkin lymphoma
Connie Lee Batlevi et al.
HAEMATOLOGICA (2016)
A phase II study of SB939, a novel pan-histone deacetylase inhibitor, in patients with translocation-associated recurrent/metastatic sarcomas-NCIC-CTG IND 200
Q. S. -C. Chu et al.
ANNALS OF ONCOLOGY (2015)
Chemotherapy induces Notch1-dependent MRP1 up-regulation, inhibition of which sensitizes breast cancer cells to chemotherapy
Baek Kim et al.
BMC CANCER (2015)
A DNA Hypomethylation Signature Predicts Antitumor Activity of LSD1 inhibitors in SCLC
Helai P. Mohammad et al.
CANCER CELL (2015)
Cooperatively transcriptional and epigenetic regulation of sonic hedgehog overexpression drives malignant potential of breast cancer
Zhao-Heng Duan et al.
CANCER SCIENCE (2015)
The Long Noncoding RNA IncTCF7 Promotes Self-Renewal of Human Liver Cancer Stem Cells through Activation of Wnt Signaling
Yanying Wang et al.
CELL STEM CELL (2015)
Histone demethylases in chromatin biology and beyond
Emilia Dimitrova et al.
EMBO REPORTS (2015)
A phase II study of the HDAC inhibitor SB939 in patients with castration resistant prostate cancer: NCIC clinical trials group study IND195
B. J. Eigl et al.
INVESTIGATIONAL NEW DRUGS (2015)
Belinostat in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma: Results of the Pivotal Phase II BELIEF (CLN-19) Study
Owen A. O'Connor et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Combination therapy with epigenetic-targeted and chemotherapeutic drugs delivered by nanoparticles to enhance the chemotherapy response and overcome resistance by breast cancer stem cells
Shi-Yong Li et al.
JOURNAL OF CONTROLLED RELEASE (2015)
Safety and tolerability of guadecitabine (SGI-110) in patients with myelodysplastic syndrome and acute myeloid leukaemia: a multicentre, randomised, dose-escalation phase 1 study
Jean-Pierre J. Issa et al.
LANCET ONCOLOGY (2015)
Notch Reporter Activity in Breast Cancer Cell Lines Identifies a Subset of Cells with Stem Cell Activity
Rosemarie C. D'Angelo et al.
MOLECULAR CANCER THERAPEUTICS (2015)
Histone Deacetylase Inhibitor Entinostat Inhibits Tumor-Initiating Cells in Triple-Negative Breast Cancer Cells
Amanda Schech et al.
MOLECULAR CANCER THERAPEUTICS (2015)
Epigenetic targets and drug discovery Part 2: Histone demethylation and DNA methylation
Ke Liu et al.
PHARMACOLOGY & THERAPEUTICS (2015)
Targeting histone lysine methylation in cancer
John McGrath et al.
PHARMACOLOGY & THERAPEUTICS (2015)
Concise Review: Targeting Cancer Stem Cells Using Immunologic Approaches
Qin Pan et al.
STEM CELLS (2015)
Epigenetic therapy for solid tumors: from bench science to clinical trials
Yen-Yi Juo et al.
EPIGENOMICS (2015)
The SUV39H1 inhibitor chaetocin induces differentiation and shows synergistic cytotoxicity with other epigenetic drugs in acute myeloid leukemia cells
Y-S Lai et al.
BLOOD CANCER JOURNAL (2015)
Inhibition of BET bromodomains as a therapeutic strategy for cancer drug discovery
Lei-lei Fu et al.
ONCOTARGET (2015)
Dual EZH2 and EHMT2 histone methyltransferase inhibition increases biological efficacy in breast cancer cells
Edward Curry et al.
CLINICAL EPIGENETICS (2015)
Antitumor activity of epigenetic immunomodulation combined with CTLA-4 blockade in syngeneic mouse models
A. Covre et al.
ONCOIMMUNOLOGY (2015)
Epigenetic therapy of cancer stem and progenitor cells by targeting DNA methylation machineries
Patompon Wongtrakoongate
WORLD JOURNAL OF STEM CELLS (2015)
Bmi1 regulates murine intestinal stem cell proliferation and self-renewal downstream of Notch
Erika Lopez-Arribillaga et al.
DEVELOPMENT (2015)
Integrated analysis of cancer-related pathways affected by genetic and epigenetic alterations in gastric cancer
Yukie Yoda et al.
GASTRIC CANCER (2015)
Histone lysine methyltransferase SUV39H1 is a potent target for epigenetic therapy of hepatocellular carcinoma
Tetsuhiro Chiba et al.
INTERNATIONAL JOURNAL OF CANCER (2015)
EMT and tumor metastasis
Sarah Heerboth et al.
CLINICAL AND TRANSLATIONAL MEDICINE (2015)
Long Residence Time Inhibition of EZH2 in Activated Polycomb Repressive Complex 2
Glenn S. Van Aller et al.
ACS CHEMICAL BIOLOGY (2014)
Epirubicin-Adsorbed Nanodiamonds Kill Chemoresistant Hepatic Cancer Stem Cells
Xin Wang et al.
ACS NANO (2014)
Potent antimyeloma activity of the novel bromodomain inhibitors I-BET151 and I-BET762
Aristeidis Chaidos et al.
BLOOD (2014)
BET-bromodomain inhibitor OTX015 shows clinically meaningful activity at nontoxic doses: interim results of an ongoing phase I trial in hematologic malignancies
Patrice E. Herait et al.
CANCER RESEARCH (2014)
Notch Signaling Drives Stemness and Tumorigenicity of Esophageal Adenocarcinoma
Zhiqiang Wang et al.
CANCER RESEARCH (2014)
Epigenetic Targeting of Ovarian Cancer Stem Cells
Yinu Wang et al.
CANCER RESEARCH (2014)
An epigenomic approach to therapy for tamoxifen-resistant breast cancer
Qin Feng et al.
CELL RESEARCH (2014)
Pre-Clinical Analysis of Changes in Intra-cellular Biochemistry of Glioblastoma Multiforme (GBM) Cells Due to c-Myc Silencing
Vishal Rajagopalan et al.
CELLULAR AND MOLECULAR NEUROBIOLOGY (2014)
Small Molecule Control of Chromatin Remodeling
Aidan Finley et al.
CHEMISTRY & BIOLOGY (2014)
EZH2 Inhibitor Efficacy in Non-Hodgkin's Lymphoma Does Not Require Suppression of H3K27 Monomethylation
William D. Bradley et al.
CHEMISTRY & BIOLOGY (2014)
The Novel, Small-Molecule DNA Methylation Inhibitor SGI-110 as an Ovarian Cancer Chemosensitizer
Fang Fang et al.
CLINICAL CANCER RESEARCH (2014)
BET bromodomain inhibitors: a patent review
Jean-Marc Garnier et al.
EXPERT OPINION ON THERAPEUTIC PATENTS (2014)
The BET Bromodomain Inhibitor I-BET151 Acts Downstream of Smoothened Protein to Abrogate the Growth of Hedgehog Protein-driven Cancers
Jun Long et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2014)
New and emerging HDAC inhibitors for cancer treatment
Alison C. West et al.
JOURNAL OF CLINICAL INVESTIGATION (2014)
Harnessing the potential of epigenetic therapy to target solid tumors
Nita Ahuja et al.
JOURNAL OF CLINICAL INVESTIGATION (2014)
Notch signaling and EMT in non-small cell lung cancer: biological significance and therapeutic application
Xun Yuan et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2014)
The Discovery of I-BET726 (GSK1324726A), a Potent Tetrahydroquinoline ApoA1 Up-Regulator and Selective BET Bromodomain Inhibitor
Romain Gosmini et al.
JOURNAL OF MEDICINAL CHEMISTRY (2014)
The H3K9 methyltransferase G9a is a marker of aggressive ovarian cancer that promotes peritoneal metastasis
Kuo-Tai Hua et al.
MOLECULAR CANCER (2014)
Selective Inhibition of EZH2 by EPZ-6438 Leads to Potent Antitumor Activity in EZH2-Mutant Non-Hodgkin Lymphoma
Sarah K. Knutson et al.
MOLECULAR CANCER THERAPEUTICS (2014)
Cancer Epigenetics: Tumor Heterogeneity, Plasticity of Stem-like States, and Drug Resistance
Hariharan Easwaran et al.
MOLECULAR CELL (2014)
A phase 2 study of belinostat (PXD101) in patients with relapsed or refractory acute myeloid leukemia or patients over the age of 60 with newly diagnosed acute myeloid leukemia: a California Cancer Consortium Study
Mark H. Kirschbaum et al.
LEUKEMIA & LYMPHOMA (2014)
Notch inhibition allows oncogene-independent generation of iPS cells
Justin K. Ichida et al.
NATURE CHEMICAL BIOLOGY (2014)
Therapeutic modulation of Notch signalling - are we there yet?
Emma R. Andersson et al.
NATURE REVIEWS DRUG DISCOVERY (2014)
Epigenetic targets and drug discovery Part 1: Histone methylation
Yanli Liu et al.
PHARMACOLOGY & THERAPEUTICS (2014)
Eradication of metastatic mouse cancers resistant to immune checkpoint blockade by suppression of myeloid-derived cells
KiBem Kim et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2014)
Immune regulation by low doses of the DNA methyltransferase inhibitor 5-azacitidine in common human epithelial cancers
Huili Li et al.
ONCOTARGET (2014)
DOT1L Inhibitor EPZ-5676 Displays Synergistic Antiproliferative Activity in Combination with Standard of Care Drugs and Hypomethylating Agents in MLL-Rearranged Leukemia Cells
Christine R. Klaus et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2014)
BIX-01294 induces autophagy-associated cell death via EHMT2/G9a dysfunction and intracellular reactive oxygen species production
Yunha Kim et al.
AUTOPHAGY (2013)
Potent inhibition of DOT1L as treatment of MLL-fusion leukemia
Scott R. Daigle et al.
BLOOD (2013)
Cbl ubiquitination of p85 is essential for Epo-induced EpoR endocytosis
Gamze B. Bulut et al.
BLOOD (2013)
A phase II trial of panobinostat in patients with advanced pretreated soft tissue sarcoma. A study from the French Sarcoma Group
P. A. Cassier et al.
BRITISH JOURNAL OF CANCER (2013)
Discovery and Characterization of Super-Enhancer-Associated Dependencies in Diffuse Large B Cell Lymphoma
Bjoern Chapuy et al.
CANCER CELL (2013)
ROS Production and NF-κB Activation Triggered by RAC1 Facilitate WNT-Driven Intestinal Stem Cell Proliferation and Colorectal Cancer Initiation
Kevin B. Myant et al.
CELL STEM CELL (2013)
Panobinostat activity in both bexarotene-exposed and -naive patients with refractory cutaneous T-cell lymphoma: Results of a phase II trial
Madeleine Duvic et al.
EUROPEAN JOURNAL OF CANCER (2013)
DNA methyltransferase 1 is essential for initiation of the colon cancers
Rena Morita et al.
EXPERIMENTAL AND MOLECULAR PATHOLOGY (2013)
Epigenetic control of epithelial-to-mesenchymal transition and cancer metastasis
Yan Wang et al.
EXPERIMENTAL CELL RESEARCH (2013)
Randomized Phase II, Double-Blind, Placebo-Controlled Study of Exemestane With or Without Entinostat in Postmenopausal Women With Locally Recurrent or Metastatic Estrogen Receptor-Positive Breast Cancer Progressing on Treatment With a Nonsteroidal Aromatase Inhibitor
Denise A. Yardley et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Notch1 is required for hypoxia-induced proliferation, invasion and chemoresistance of T-cell acute lymphoblastic leukemia cells
Jie Zou et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2013)
Discovery of an in Vivo Chemical Probe of the Lysine Methyltransferases G9a and GLP
Feng Liu et al.
JOURNAL OF MEDICINAL CHEMISTRY (2013)
Improving Sensitivity to Irinotecan Using 5-Azacytidine in Colon Cancer Cell Lines
R.J. Vatapalli et al.
JOURNAL OF SURGICAL RESEARCH (2013)
The future of epigenetic therapy in solid tumours-lessons from the past
Nilofer Azad et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2013)
Histone lysine demethylases as targets for anticancer therapy
Jonas W. Hojfeldt et al.
NATURE REVIEWS DRUG DISCOVERY (2013)
The Polycomb complex PRC2 supports aberrant self-renewal in a mouse model of MLL-AF9;NrasG12D acute myeloid leukemia
J. Shi et al.
ONCOGENE (2013)
Targeting genetic alterations in protein methyltransferases for personalized cancer therapeutics
R. A. Copeland et al.
ONCOGENE (2013)
A Phase I Study of Histone Deacetylase Inhibitor, Pracinostat (SB939), in Pediatric Patients With Refractory Solid Tumors: IND203 a Trial of the NCIC IND Program/C17 Pediatric Phase I Consortium
Alexandra P. Zorzi et al.
PEDIATRIC BLOOD & CANCER (2013)
BET Inhibition Silences Expression of MYCN and BCL2 and Induces Cytotoxicity in Neuroblastoma Tumor Models
Anastasia Wyce et al.
PLOS ONE (2013)
Durable tumor regression in genetically altered malignant rhabdoid tumors by inhibition of methyltransferase EZH2
Sarah K. Knutson et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
Efficacy of Using Cancer Stem Cell Markers in Isolating and Characterizing Liver Cancer Stem Cells
George S. Wilson et al.
STEM CELLS AND DEVELOPMENT (2013)
Analysis of the levels of lysine-specific demethylase 1 (LSD1) mRNA in human ovarian tumors and the effects of chemical LSD1 inhibitors in ovarian cancer cell lines
Sergiy Konovalov et al.
JOURNAL OF OVARIAN RESEARCH (2013)
Inhibition of BET bromodomain proteins as a therapeutic approach in prostate cancer
Anastasia Wyce et al.
ONCOTARGET (2013)
The polycomb group protein EZH2 is a novel therapeutic target in tongue cancer
Zhongwu Li et al.
ONCOTARGET (2013)
An Aberrant Transcription Factor Network Essential for Wnt Signaling and Stem Cell Maintenance in Glioblastoma
Esther Rheinbay et al.
CELL REPORTS (2013)
Phase I-II study of vorinostat plus paclitaxel and bevacizumab in metastatic breast cancer: evidence for vorinostat-induced tubulin acetylation and Hsp90 inhibition in vivo
B. Ramaswamy et al.
BREAST CANCER RESEARCH AND TREATMENT (2012)
The Histone Demethylase KDM1A Sustains the Oncogenic Potential of MLL-AF9 Leukemia Stem Cells
William J. Harris et al.
CANCER CELL (2012)
Transient Low Doses of DNA-Demethylating Agents Exert Durable Antitumor Effects on Hematological and Epithelial Tumor Cells
Hsing-Chen Tsai et al.
CANCER CELL (2012)
Epigenetic Resensitization to Platinum in Ovarian Cancer
Daniela Matei et al.
CANCER RESEARCH (2012)
Conformational Adaptation Drives Potent, Selective and Durable Inhibition of the Human Protein Methyltransferase DOT1L
Aravind Basavapathruni et al.
CHEMICAL BIOLOGY & DRUG DESIGN (2012)
The BRD-inhibitor OTX015 Shows Pre-clinical Activity in Diffuse Large B-cell Lymphoma (DLBCL)
P. Bonetti et al.
EUROPEAN JOURNAL OF CANCER (2012)
LSD1 inhibition: a therapeutic strategy in cancer?
James T. Lynch et al.
EXPERT OPINION ON THERAPEUTIC TARGETS (2012)
A phase II evaluation of belinostat and carboplatin in the treatment of recurrent or persistent platinum-resistant ovarian, fallopian tube, or primary peritoneal carcinoma: A gynecologic oncology group study
Don S. Dizon et al.
GYNECOLOGIC ONCOLOGY (2012)
Oncogene-specific formation of chemoresistant murine hepatic cancer stem cells
Edward Kai-Hua Chow et al.
HEPATOLOGY (2012)
Targeting the Unique Methylation Pattern of Androgen Receptor (AR) Promoter in Prostate Stem/Progenitor Cells with 5-Aza-2′-deoxycytidine (5-AZA) Leads to Suppressed Prostate Tumorigenesis
Jing Tian et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2012)
Panobinostat in Patients With Relapsed/Refractory Hodgkin's Lymphoma After Autologous Stem-Cell Transplantation: Results of a Phase II Study
Anas Younes et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Epigenetic Therapy Using Belinostat for Patients With Unresectable Hepatocellular Carcinoma: A Multicenter Phase I/II Study With Biomarker and Pharmacokinetic Analysis of Tumors From Patients in the Mayo Phase II Consortium and the Cancer Therapeutics Research Group
Winnie Yeo et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Randomized Phase II Trial of Erlotinib With and Without Entinostat in Patients With Advanced Non-Small-Cell Lung Cancer Who Progressed on Prior Chemotherapy
Samir E. Witta et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Epigenetic alterations involved in cancer stem cell reprogramming
Purificacion Munoz et al.
MOLECULAR ONCOLOGY (2012)
Lysine-specific demethylase 1 restricts hematopoietic progenitor proliferation and is essential for terminal differentiation
A. Spruessel et al.
LEUKEMIA (2012)
A selective jumonji H3K27 demethylase inhibitor modulates the proinflammatory macrophage response
Laurens Kruidenier et al.
NATURE (2012)
EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations
Michael T. McCabe et al.
NATURE (2012)
Inhibition of the LSD1 (KDM1A) demethylase reactivates the all-trans-retinoic acid differentiation pathway in acute myeloid leukemia
Tino Schenk et al.
NATURE MEDICINE (2012)
Epigenetic protein families: a new frontier for drug discovery
Cheryl H. Arrowsmith et al.
NATURE REVIEWS DRUG DISCOVERY (2012)
Safety and Activity of Anti-PD-L1 Antibody in Patients with Advanced Cancer
Julie R. Brahmer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Safety, Activity, and Immune Correlates of Anti-PD-1 Antibody in Cancer
Suzanne L. Topalian et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Wnt/β-Catenin Signaling Regulates Telomerase in Stem Cells and Cancer Cells
Katrin Hoffmeyer et al.
SCIENCE (2012)
Notch Signaling
Raphael Kopan
COLD SPRING HARBOR PERSPECTIVES IN BIOLOGY (2012)
Emerging Epigenetic Targets and Therapies in Cancer Medicine
Relja Popovic et al.
CANCER DISCOVERY (2012)
Current trends in the development of histone deacetylase inhibitors: a review of recent patent applications
Florian Thaler
PHARMACEUTICAL PATENT ANALYST (2012)
Basal cell carcinoma: cell of origin, cancer stem cell hypothesis and stem cell markers
K. Sellheyer
BRITISH JOURNAL OF DERMATOLOGY (2011)
Phase 1b-2a Study to Reverse Platinum Resistance Through Use of a Hypomethylating Agent, Azacitidine, in Patients With Platinum-Resistant or Platinum-Refractory Epithelial Ovarian Cancer
Siqing Fu et al.
CANCER (2011)
Continued Azacitidine Therapy Beyond Time of First Response Improves Quality of Response in Patients With Higher-Risk Myelodysplastic Syndromes
Lewis R. Silverman et al.
CANCER (2011)
Selective Killing of Mixed Lineage Leukemia Cells by a Potent Small-Molecule DOT1L Inhibitor
Scott R. Daigle et al.
CANCER CELL (2011)
FoxM1 Promotes β-Catenin Nuclear Localization and Controls Wnt Target-Gene Expression and Glioma Tumorigenesis
Nu Zhang et al.
CANCER CELL (2011)
Using a Stem Cell-Based Signature to Guide Therapeutic Selection in Cancer
Igor Shats et al.
CANCER RESEARCH (2011)
EMT and Stem Cell-Like Properties Associated with miR-205 and miR-200 Epigenetic Silencing Are Early Manifestations during Carcinogen-Induced Transformation of Human Lung Epithelial Cells
Carmen S. Tellez et al.
CANCER RESEARCH (2011)
BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-Myc
Jake E. Delmore et al.
CELL (2011)
Notch signaling: simplicity in design, versatility in function
Emma R. Andersson et al.
DEVELOPMENT (2011)
Histone Deacetylase Inhibitors in the Treatment of Hematological Malignancies and Solid Tumors
Mario Federico et al.
JOURNAL OF BIOMEDICINE AND BIOTECHNOLOGY (2011)
Methylation of the promoter of human leukocyte antigen class I in human esophageal squamous cell carcinoma and its histopathological characteristics
Sun Qifeng et al.
JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY (2011)
Pharmacologic disruption of Polycomb Repressive Complex 2 inhibits tumorigenicity and tumor progression in prostate cancer
Francesco Crea et al.
MOLECULAR CANCER (2011)
Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia
Mark A. Dawson et al.
NATURE (2011)
p53 regulates epithelial-mesenchymal transition and stem cell properties through modulating miRNAs
Chun-Ju Chang et al.
NATURE CELL BIOLOGY (2011)
A chemical probe selectively inhibits G9a and GLP methyltransferase activity in cells
Masoud Vedadi et al.
NATURE CHEMICAL BIOLOGY (2011)
Stem cell gene expression programs influence clinical outcome in human leukemia
Kolja Eppert et al.
NATURE MEDICINE (2011)
A phase I/II trial of the histone deacetylase inhibitor romidepsin for adults with recurrent malignant glioma: North American Brain Tumor Consortium Study 03-03
Fabio M. Iwamoto et al.
NEURO-ONCOLOGY (2011)
Notch1 regulates the expression of the multidrug resistance gene ABCC1/MRP1 in cultured cancer cells
Sungpil Cho et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)
Targeting MYC dependence in cancer by inhibiting BET bromodomains
Jennifer A. Mertz et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)
Combination Epigenetic Therapy Has Efficacy in Patients with Refractory Advanced Non-Small Cell Lung Cancer
Rosalyn A. Juergens et al.
CANCER DISCOVERY (2011)
Enhanced Expression of EHMT2 Is Involved in the Proliferation of Cancer Cells through Negative Regulation of SIAH1
Hyun-Soo Cho et al.
NEOPLASIA (2011)
Phase II, two-stage, single-arm trial of the histone deacetylase inhibitor (HDACi) romidepsin in metastatic castration-resistant prostate cancer (CRPC)
L. R. Molife et al.
ANNALS OF ONCOLOGY (2010)
PLAGL2 Regulates Wnt Signaling to Impede Differentiation in Neural Stem Cells and Gliomas
Hongwu Zheng et al.
CANCER CELL (2010)
H3K9 Histone Methyltransferase G9a Promotes Lung Cancer Invasion and Metastasis by Silencing the Cell Adhesion Molecule Ep-CAM
Min-Wei Chen et al.
CANCER RESEARCH (2010)
The AC133 Epitope, but not the CD133 Protein, Is Lost upon Cancer Stem Cell Differentiation
Kristel Kemper et al.
CANCER RESEARCH (2010)
Expression and regulation mechanisms of Sonic Hedgehog in breast cancer
Wei Cui et al.
CANCER SCIENCE (2010)
A Chromatin-Mediated Reversible Drug-Tolerant State in Cancer Cell Subpopulations
Sreenath V. Sharma et al.
CELL (2010)
BRCA1 Basal-like Breast Cancers Originate from Luminal Epithelial Progenitors and Not from Basal Stem Cells
Gemma Molyneux et al.
CELL STEM CELL (2010)
Phase II trial of the histone deacetylase inhibitor belinostat in women with platinum resistant epithelial ovarian cancer and micropapillary (LMP) ovarian tumours
Helen J. Mackay et al.
EUROPEAN JOURNAL OF CANCER (2010)
α2,3-Sialylation regulates the stability of stem cell marker CD133
Fengbiao Zhou et al.
JOURNAL OF BIOCHEMISTRY (2010)
G9a and Glp Methylate Lysine 373 in the Tumor Suppressor p53
Jing Huang et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2010)
Mammalian target of rapamycin regulates murine and human cell differentiation through STAT3/p63/Jagged/Notch cascade
Jianhui Ma et al.
JOURNAL OF CLINICAL INVESTIGATION (2010)
Final Results From a Multicenter, International, Pivotal Study of Romidepsin in Refractory Cutaneous T-Cell Lymphoma
Sean J. Whittaker et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Phase II Study of the Histone Deacetylase Inhibitor Romidepsin in Relapsed Small Cell Lung Cancer (Cancer and Leukemia Group B 30304)
Gregory A. Otterson et al.
JOURNAL OF THORACIC ONCOLOGY (2010)
Jmjd3 and UTX Play a Demethylase-Independent Role in Chromatin Remodeling to Regulate T-Box Family Member-Dependent Gene Expression
Sara A. Miller et al.
MOLECULAR CELL (2010)
Suppression of inflammation by a synthetic histone mimic
Edwige Nicodeme et al.
NATURE (2010)
Selective inhibition of BET bromodomains
Panagis Filippakopoulos et al.
NATURE (2010)
Histone deacetylase and Cullin3-RENKCTD11 ubiquitin ligase interplay regulates Hedgehog signalling through Gli acetylation
Gianluca Canettieri et al.
NATURE CELL BIOLOGY (2010)
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
F. Stephen Hodi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Reexpression of epigenetically silenced AML tumor suppressor genes by SUV39H1 inhibition
A. Lakshmikuttyamma et al.
ONCOGENE (2010)
Essential Role of the Histone Methyltransferase G9a in Cocaine-Induced Plasticity
Ian Maze et al.
SCIENCE (2010)
Hypermethylation of HLA class I gene is associated with HLA class I down-regulation in human gastric cancer
Q. Ye et al.
TISSUE ANTIGENS (2010)
Will DNA methylation inhibitors work in solid tumors? A review of the clinical experience with azacitidine and decitabine in solid tumors
Lisa A. Cowan et al.
EPIGENOMICS (2010)
Reversal of ABC Drug Transporter-Mediated Multidrug Resistance in Cancer Cells: Evaluation of Current Strategies
Chung-Pu Wu et al.
Current Molecular Pharmacology (2010)
Antitumor Effects of a Combined 5-Aza-2′Deoxycytidine and Valproic Acid Treatment on Rhabdomyosarcoma and Medulloblastoma in Ptch Mutant Mice
Ines Ecke et al.
CANCER RESEARCH (2009)
Loss of the SMRT/NCoR2 Corepressor Correlates with JAG2 Overexpression in Multiple Myeloma
Pushpankur Ghoshal et al.
CANCER RESEARCH (2009)
EZH2 Is Essential for Glioblastoma Cancer Stem Cell Maintenance
Mario-Luca Suva et al.
CANCER RESEARCH (2009)
Tobacco Smoke Induces Polycomb-Mediated Repression of Dickkopf-1 in Lung Cancer Cells
Mustafa Hussain et al.
CANCER RESEARCH (2009)
Acquisition of Epithelial-Mesenchymal Transition Phenotype of Gemcitabine-Resistant Pancreatic Cancer Cells Is Linked with Activation of the Notch Signaling Pathway
Zhiwei Wang et al.
CANCER RESEARCH (2009)
Epithelial to Mesenchymal Transition Contributes to Drug Resistance in Pancreatic Cancer
Thiruvengadam Arumugam et al.
CANCER RESEARCH (2009)
Epithelial-Mesenchymal Transitions in Development and Disease
Jean Paul Thiery et al.
CELL (2009)
EpCAM-Positive Hepatocellular Carcinoma Cells Are Tumor-Initiating Cells With Stem/Progenitor Cell Features
Taro Yamashita et al.
GASTROENTEROLOGY (2009)
Contextual extracellular cues promote tumor cell EMT and metastasis by regulating miR-200 family expression
Don L. Gibbons et al.
GENES & DEVELOPMENT (2009)
Epigenetic reprogramming of breast cancer cells by valproic acid occurs regardless of estrogen receptor status
Lorena Travaglini et al.
INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY (2009)
Phase II trial of romidepsin (NSC-630176) in previously treated colorectal cancer patients with advanced disease: a Southwest Oncology Group study (S0336)
Robert P. Whitehead et al.
INVESTIGATIONAL NEW DRUGS (2009)
Dynamic Histone H1 Isotype 4 Methylation and Demethylation by Histone Lysine Methyltransferase G9a/KMT1C and the Jumonji Domain-containing JMJD2/KDM4 Proteins
Patrick Trojer et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2009)
Lack of Therapeutic Effect of the Histone Deacetylase Inhibitor Vorinostat in Patients with Metastatic Radioiodine-Refractory Thyroid Carcinoma
Jennifer A. Woyach et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2009)
Histone Deacetylase Inhibitors in Cancer Therapy
Andrew A. Lane et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Phase II Trial of Vorinostat in Recurrent Glioblastoma Multiforme: A North Central Cancer Treatment Group Study
Evanthia Galanis et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Phase II Multi-Institutional Trial of the Histone Deacetylase Inhibitor Romidepsin As Monotherapy for Patients With Cutaneous T-Cell Lymphoma
Richard L. Piekarz et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Vorinostat (NSC# 701852) in Patients with Relapsed Non-small Cell Lung Cancer A Wisconsin Oncology Network Phase II Study
Anne M. Traynor et al.
JOURNAL OF THORACIC ONCOLOGY (2009)
DZNep is a global histone methylation inhibitor that reactivates developmental genes not silenced by DNA methylation
Tina Branscombe Miranda et al.
MOLECULAR CANCER THERAPEUTICS (2009)
DNA methylation protects hematopoietic stem cell multipotency from myeloerythroid restriction
Ann-Marie Broeske et al.
NATURE GENETICS (2009)
Aberrant luminal progenitors as the candidate target population for basal tumor development in BRCA1 mutation carriers
Elgene Lim et al.
NATURE MEDICINE (2009)
Protein methyltransferases as a target class for drug discovery
Robert A. Copeland et al.
NATURE REVIEWS DRUG DISCOVERY (2009)
DACT3 is an epigenetic regulator of Wnt/β-catenin signaling in colorectal cancer and is a therapeutic target of histone modifications
Xia Jiang et al.
CANCER CELL (2008)
H3K79 Methylation Profiles Define Murine and Human MLL-AF4 Leukemias
Andrei V. Krivtsov et al.
CANCER CELL (2008)
Acquisition of granule neuron precursor identity is a critical determinant of progenitor cell competence to form Shh-induced medulloblastoma
Ulrich Schueller et al.
CANCER CELL (2008)
Medulloblastoma can be initiated by deletion of patched in lineage-restricted progenitors or stem cells
Zeng-Jie Yang et al.
CANCER CELL (2008)
Identification and characterization of ovarian cancer-initiating cells from primary human tumors
Shu Zhang et al.
CANCER RESEARCH (2008)
The epithelial-mesenchymal transition generates cells with properties of stem cells
Sendurai A. Mani et al.
CELL (2008)
The upstream components of the Wnt signalling pathway in the dynamic EMT and MET associated with colorectal cancer progression
Elizabeth Vincan et al.
CLINICAL & EXPERIMENTAL METASTASIS (2008)
Clinical and molecular responses in lung cancer patients receiving Romidepsin
David S. Schrump et al.
CLINICAL CANCER RESEARCH (2008)
A Phase II Trial of Vorinostat (Suberoylanilide Hydroxamic Acid) in Metastatic Breast Cancer: A California Cancer Consortium Study
Thehang H. Luu et al.
CLINICAL CANCER RESEARCH (2008)
Epithelial-mesenchymal transition: At the crossroads of development and tumor metastasis
Jing Yang et al.
DEVELOPMENTAL CELL (2008)
Epigenetic gene silencing in the Wnt pathway in breast cancer
George J. Klarmann et al.
EPIGENETICS (2008)
The miR-200 family determines the epithelial phenotype of cancer cells by targeting the E-cadherin repressors ZEB1 and ZEB2
Sun-Mi Park et al.
GENES & DEVELOPMENT (2008)
A phase II study of vorinostat in the treatment of persistent or recurrent epithelial ovarian or primary peritoneal carcinoma: A Gynecologic Oncology Group study
Susan C. Modesitt et al.
GYNECOLOGIC ONCOLOGY (2008)
Modes of action of the DNA methyltransferase inhibitors azacytidine and decitabine
Carlo Stresemann et al.
INTERNATIONAL JOURNAL OF CANCER (2008)
Early phase II trial of oral vorinostat in relapsed or refractory breast, colorectal, or non-small cell lung cancer
Johan Vansteenkiste et al.
INVESTIGATIONAL NEW DRUGS (2008)
The miR-200 family inhibits epithelial-mesenchymal transition and cancer cell migration by direct targeting of E-cadherin transcriptional repressors ZEB1 and ZEB2
Manav Korpal et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2008)
DOT1L/KMT4 recruitment and H3K79 methylation are ubiquitously coupled with gene transcription in mammalian cells
David J. Steger et al.
MOLECULAR AND CELLULAR BIOLOGY (2008)
Polycomb complex 2 is required for E-cadherin repression by the snail1 transcription factor
Nicolas Herranz et al.
MOLECULAR AND CELLULAR BIOLOGY (2008)
Histone modifications at the ABCG2 promoter following treatment with histone deacetylase inhibitor mirror those in multidrug-resistant cells
Kenneth K. W. To et al.
MOLECULAR CANCER RESEARCH (2008)
Roles of the EZH2 histone methyltransferase in cancer epigenetics
Jeffrey A. Simon et al.
MUTATION RESEARCH-FUNDAMENTAL AND MOLECULAR MECHANISMS OF MUTAGENESIS (2008)
Identification of cells initiating human melanomas
Tobias Schatton et al.
NATURE (2008)
Efficient tumour formation by single human melanoma cells
Elsa Quintana et al.
NATURE (2008)
The mir-200 family and mir-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1
Philip A. Gregory et al.
NATURE CELL BIOLOGY (2008)
Combinatorial patterns of histone acetylations and methylations in the human genome
Zhibin Wang et al.
NATURE GENETICS (2008)
Repression of E-cadherin by the polycomb group protein EZH2 in cancer
Q. Cao et al.
ONCOGENE (2008)
Downregulation of Histone H3 Lysine 9 Methyltransferase G9a Induces Centrosome Disruption and Chromosome Instability in Cancer Cells
Yutaka Kondo et al.
PLOS ONE (2008)
Generation of Breast Cancer Stem Cells through Epithelial-Mesenchymal Transition
Anne-Pierre Morel et al.
PLOS ONE (2008)
Sustained induction of epithelial to mesenchymal transition activates DNA methylation of genes silenced in basal-like breast cancers
Nancy Dumont et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
Identification and expansion of the tumorigenic lung cancer stem cell population
A. Eramo et al.
CELL DEATH AND DIFFERENTIATION (2008)
Phase II trial of the histone deacetylase inhibitor vorinostat (Zolinza™, suberoylanilide hydroxamic acid, SAHA) in patients with recurrent and/or metastatic head and neck cancer
George R. Blumenschein et al.
INVESTIGATIONAL NEW DRUGS (2008)
A role for the MLL fusion partner ENL in transcriptional elongation and chromatin modification
Dorothee Mueller et al.
BLOOD (2007)
Development and characterization of gemcitabine-resistant pancreatic tumor cells
Ami N. Shah et al.
ANNALS OF SURGICAL ONCOLOGY (2007)
Covalent modifications of histones during development and disease pathogenesis
Sukesh R. Bhaumik et al.
NATURE STRUCTURAL & MOLECULAR BIOLOGY (2007)
Alterations of DNA methylation and histone modifications contribute to gene silencing in hepatocellular carcinomas
Yutaka Kondo et al.
HEPATOLOGY RESEARCH (2007)
Demethylation of H3K27 regulates polycomb recruitment and H2A ubiquitination
Min Gyu Lee et al.
SCIENCE (2007)
UTX and JMJD3 are histone H3K27 demethylases involved in HOX gene regulation and development
Karl Agger et al.
NATURE (2007)
A histone H3 lysine 27 demethylase regulates animal posterior development
Fei Lan et al.
NATURE (2007)
Phase I and pharmacodynamic trial of the DNA methyltransferase inhibitor decitabine and carboplatin in solid tumors
Kim Appleton et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
LSD1 and the chemistry of histone demethylation
Jeffrey C. Culhane et al.
CURRENT OPINION IN CHEMICAL BIOLOGY (2007)
Down-regulation of HILA class I antigens in prostate cancer tissues and up-regulation by histone deacetylase inhibition
Hiroshi Kitamura et al.
JOURNAL OF UROLOGY (2007)
Phase IIB multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma
Elise A. Olsen et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
PTIP associates with MLL3-and MLL4-containing histone H3 lysine 4 methyltransferase complex
Young-Wook Cho et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2007)
The Wnt5A/protein kinase C pathway mediates motility in melanoma cells via the inhibition of metastasis suppressors and initiation of an epithelial to mesenchymal transition
Samudra K. Dissanayake et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2007)
Identification and characterization of tumorigenic liver cancer stem/progenitor cells
Stephanie Ma et al.
GASTROENTEROLOGY (2007)
Stability and flexibility of epigenetic gene regulation in mammalian development
Wolf Reik
NATURE (2007)
Pharmacologic disruption of polycomb-repressive complex 2-mediated gene repression selectively induces apoptosis in cancer cells
Jing Tan et al.
GENES & DEVELOPMENT (2007)
CD133+ and CD133- glioblastoma-derived cancer stem cells show differential growth characteristics and molecular profiles
Dagmar Beier et al.
CANCER RESEARCH (2007)
Epigenetic gene silencing in cancer: the DNA hypermethylome
Manel Esteller
HUMAN MOLECULAR GENETICS (2007)
Knockdown of ALR (MLL2) reveals ALR target genes and leads to alterations in cell adhesion and growth
Irina Issaeva et al.
MOLECULAR AND CELLULAR BIOLOGY (2007)
Chromatin modifications and their function
Tony Kouzarides
CELL (2007)
Reversal of H3K9me2 by a small-molecule inhibitor for the G9a histone methyltransferase
Stefan Kubicek et al.
MOLECULAR CELL (2007)
A stem cell-like chromatin pattern may predispose tumor suppressor genes to DNA hypermethylation and heritable silencing
Joyce E. Ohm et al.
NATURE GENETICS (2007)
Identification and expansion of human colon-cancer-initiating cells
Lucia Ricci-Vitiani et al.
NATURE (2007)
The mixed-lineage leukemia fusion partner AF4 stimulates RNA polymerase II transcriptional elongation and mediates coordinated chromatin remodeling
Emmanuelle Bitoun et al.
HUMAN MOLECULAR GENETICS (2007)
Cyclopamine-mediated hedgehog pathway inhibition depletes stem-like cancer cells in glioblastoma
Eli E. Bar et al.
STEM CELLS (2007)
Wnt signalingg stem cells and the cellular origin of breast cancer
Charlotta Lindvall et al.
STEM CELL REVIEWS (2007)
Up-regulation of HLA class-I antigen expression and antigen-specific CTL response in cervical cancer cells by the demethylating agent hydralazine and the histone deacetylase inhibitor valproic acid
Maria de Lourdes Mora-Garcia et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2006)
Mining the Wnt pathway for cancer therapeutics
Nick Barker et al.
NATURE REVIEWS DRUG DISCOVERY (2006)
Angiogenesis-independent tumor growth mediated by stem-like cancer cells
Per O. Sakariassen et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
The connectivity map: Using gene-expression signatures to connect small molecules, genes, and disease
Justin Lamb et al.
SCIENCE (2006)
Notch signalling regulates stem cell numbers in vitro and in vivo
Andreas Androutsellis-Theotokis et al.
NATURE (2006)
Dot1a-AF9 complex mediates histone H3 Lys-79 hypermethylation and repression of ENaCα in an aldosterone-sensitive manner
Wenzheng Zhang et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2006)
A phase II study of depsipeptide in refractory metastatic renal cell cancer
Walter M. Stadler et al.
CLINICAL GENITOURINARY CANCER (2006)
Cyclooxygenase-2-dependent regulation of E-cadherin:: Prostaglandin E2 induces transcriptional repressors ZEB1 and snail in non-small cell lung cancer
Mariam Dohadwala et al.
CANCER RESEARCH (2006)
Genome-wide mapping of Polycomb target genes unravels their roles in cell fate transitions
AP Bracken et al.
GENES & DEVELOPMENT (2006)
Increased expression of sonic hedgehog and altered methylation of its promoter region in gastric cancer and its related lesions
LH Wang et al.
MODERN PATHOLOGY (2006)
JmjC-domain-containing proteins and histone demethylation
Robert J. Klose et al.
NATURE REVIEWS GENETICS (2006)
Prospective identification of tumorigenic prostate cancer stem cells
AT Collins et al.
CANCER RESEARCH (2005)
5-Aza-deoxycytidine induces selective degradation of DNA methyltransferase 1 by a proteasomal pathway that requires the KEN box, bromo-adjacent homology domain, and nuclear localization signal
K Ghoshal et al.
MOLECULAR AND CELLULAR BIOLOGY (2005)
hDOT1L links histone methylation to leukemogenesis
Y Okada et al.
CELL (2005)
Interaction of PD-L1 on tumor cells with PD-1 on tumor-specific T cells as a mechanism of immune evasion: implications for tumor immunotherapy
C Blank et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2005)
FDA drug approval summary:: Azacitidine (5-azacytidine, Vidaza™) for injectable suspension
E Kaminskas et al.
ONCOLOGIST (2005)
Histone deacetylase inhibitors down-regulate bcl-2 expression and induce apoptosis in t(14;18) lymphomas
H Duan et al.
MOLECULAR AND CELLULAR BIOLOGY (2005)
Epigenetic inactivation of SFRP genes allows constitutive WNT signaling in colorectal cancer
H Suzuki et al.
NATURE GENETICS (2004)
RENKCTD11 is a suppressor of Hedgehog signaling and is deleted in human medulloblastoma
L Di Marcotullio et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2004)
Tissue repair and stem cell renewal in carcinogenesis
PA Beachy et al.
NATURE (2004)
Identification of human brain tumour initiating cells
SK Singh et al.
NATURE (2004)
EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells
CG Kleer et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
Histone deacetylase inhibitors in cancer therapy: Is transcription the primary target?
RW Johnstone et al.
CANCER CELL (2003)
Prospective identification of tumorigenic breast cancer cells
M Al-Hajj et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
Histone deacetylases (HDACs): characterization of the classical HDAC family
AJM De Ruijter et al.
BIOCHEMICAL JOURNAL (2003)
Histone methyltransferase activity associated with a human multiprotein complex containing the Enhancer of Zeste protein
A Kuzmichev et al.
GENES & DEVELOPMENT (2002)
Role of histone H3 lysine 27 methylation in polycomb-group silencing
R Cao et al.
SCIENCE (2002)
Heterogeneity in the modification and involvement of chromatin components of the CpG island of the silenced human CDH1 gene in cancer cells
S Koizume et al.
NUCLEIC ACIDS RESEARCH (2002)
Histone methyltransferase activity of a Drosophila polycomb group repressor complex
J Müller et al.
CELL (2002)
The polycomb group protein EZH2 is involved in progression of prostate cancer
S Varambally et al.
NATURE (2002)
G9a histone methyltransferase plays a dominant role in euchromatic histone H3 lysine 9 methylation and is essential for early embryogenesis
M Tachibana et al.
GENES & DEVELOPMENT (2002)
Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells
M Göttlicher et al.
EMBO JOURNAL (2001)
Hedgehog signaling in animal development: paradigms and principles
PW Ingham et al.
GENES & DEVELOPMENT (2001)
Stem cells, cancer, and cancer stem cells
T Reya et al.
NATURE (2001)
Role of protein methylation in chromatin remodeling and transcriptional regulation
MR Stallcup
ONCOGENE (2001)
Activation of MHC class I, II, and CD40 gene expression by histone deacetylase inhibitors
WJ Magner et al.
JOURNAL OF IMMUNOLOGY (2000)
Deacetylation of p53 modulates its effect on cell growth and apoptosis
JY Luo et al.
NATURE (2000)
分享论文
